This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $21.98, moving +0.69% from the previous trading session.
Can Constellation (STZ) Keep The Party Going: Earning BMO Thursday
by Daniel Laboe
Constellation Brands is outpacing the rest of the industry with its strategic positioning and operational excellence.
Can Beer Business Aid Constellation Brands' (STZ) Q2 Earnings?
by Zacks Equity Research
Momentum in the beer business positions Constellation Brands (STZ) for solid top and bottom-line growth in second-quarter fiscal 2020.
Is Constellation Brands (STZ) Stock a Buy Heading into Q2 Earnings?
by Benjamin Rains
Should investors consider buying shares of Constellation Brands (STZ) as we head into the release of its second quarter fiscal 2020 earnings results, due out on Thursday, October 3?
Epidolex Progresses: Will the Marijuana Drug Market Boom?
by Indrajit Bandyopadhyay
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.
GW Pharma Gets EU Nod for Anti-Epileptic Drug Epidyolex
by Zacks Equity Research
GW Pharmaceuticals (GWPH) wins EU approval for Epidyolex as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged two years and above.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $25.59, marking a +0.12% move from the previous day.
Cannabis Industry to Scale New Highs Amid Legalization Woes
by Nilanjan Gupta
Legalization will likely drive commercial distribution of cannabis and boost growth of companies operating in this space.
Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?
by Benjamin Rains
Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?
What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?
by Zacks Equity Research
Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.
Implied Volatility Surging For Canopy Growth (CGC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Balanced Risk-Reward for Constellation Brands: Stock Rises
by Zacks Equity Research
Constellation Brands (STZ) witnesses strength in the beer business on strong shipment volume and depletions. But softness in the Wine & Spirits unit and Canopy Growth-related costs are headwinds.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 20.69% and -21.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth (CGC) Earnings After The Bell: How High Can They Go?
by Daniel Laboe
Canopy is the clear leader in the marijuana space with a vastly diversified portfolio of cannabis products along with its STZ partnership.
HubSpot, Kraft Heinz, CNBS, Canopy Growth, Aurora Cannabis and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
HubSpot, Kraft Heinz, CNBS, Canopy Growth, Aurora Cannabis and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Constellation Brands to Divest Black Velvet Canadian Whisky
by Zacks Equity Research
Constellation Brands (STZ) is on track with wine and spirits business transformation strategy. The company signs an agreement with Heaven Hill Brands to divest Black Velvet Canadian Whisky.
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
Tilray to Report Earnings Today: Will It Top or Flop?
by Tirthankar Chakraborty
From global marijuana legalization to the rapidly increasing use of CBD as a wellness product, all of this should help Tilray witness an uptick in second-quarter revenues.
Canopy Growth Set to Acquire Beckley Canopy Therapeutics
by Zacks Equity Research
With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
ETFs in Focus as Consolidation Drives Marijuana Industry
by Sanghamitra Saha
Deals activity has been robust in the marijuana space, paving way for gains in these cannabis ETFs.
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
The Zacks Analyst Blog Highlights: Canopy Growth and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth and Tilray
2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond
by Mitchell Moore
The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.